journal article·2017-01-02Open access

Application of nanostructured drug delivery systems in immunotherapy of cancer: a review

Nahideh Asadi, Soodabeh Davaran, Yunes Panahi, Arash Hasanzadeh, Javad Malakootikhah, Hadi Fallah Moafi, Abolfazl Akbarzadeh

Abstract

The cancer immunotherapy method uses the specificity of the immune system to provide a more effective than more conventional treatments, such as chemotherapy and radiotherapy. Immunotherapy has two main strategies (passive or active) to organize the immune system. Passive strategies use advantage of tumor-hyperpermeable cells, which have enhanced permeability and retention effects. Nanoparticles due to their better accumulation within tissues and cells of the immune system are well suitable for delivery of immune therapies such as vaccines or adjuvants. In this review, we explained application of nanotechnology in immunotherapy of cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran;

Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran;

Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;

Laboratory of Biochemistry, Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran;

Department of New Sciences and Technologies, University of Tehran, Tehran, Iran;

Department of Chemistry, Faculty of Science, University of Guilan, Rasht, Iran;

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

References (60)

Show source-provided references
1. 10.3109/21691401.2014.92788010.3109/21691401.2014.927880 ↗
2. 10.1186/1556-276X-9-24710.1186/1556-276X-9-247 ↗
3. Abbasi E · Crit Rev Microbiol · 2016 · 42 · 173
4. 10.1007/s11033-013-3014-410.1007/s11033-013-3014-4 ↗
5. 10.7314/APJCP.2014.15.1.4910.7314/APJCP.2014.15.1.49 ↗
6. Alizadeh E · Chem Biol Drug Des · 2014 · 85 · 600
7. 10.1111/cbdd.1266410.1111/cbdd.12664 ↗
8. 10.1016/j.nano.2013.09.01110.1016/j.nano.2013.09.011 ↗
9. 10.1038/nri286810.1038/nri2868 ↗
10. 10.1080/1040836090293780910.1080/10408360902937809 ↗
11. 10.1158/1078-0432.CCR-07-480410.1158/1078-0432.CCR-07-4804 ↗
12. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
13. 10.1042/CBI2009020610.1042/CBI20090206 ↗
14. 10.1016/j.coi.2006.09.00410.1016/j.coi.2006.09.004 ↗
15. 10.1038/nnano.2011.14910.1038/nnano.2011.149 ↗
16. 10.3109/21691401.2014.94464410.3109/21691401.2014.944644 ↗
17. 10.3389/fchem.2014.0010510.3389/fchem.2014.00105 ↗
18. 10.1021/mp100178k10.1021/mp100178k ↗
19. 10.3109/21691401.2014.95510710.3109/21691401.2014.955107 ↗
20. 10.3109/21691401.2014.95363310.3109/21691401.2014.953633 ↗
21. 10.7314/APJCP.2014.15.10.435310.7314/APJCP.2014.15.10.4353 ↗
22. Dimberu PM · Yale J Biol Med · 2011 · 84 · 371
23. 10.1016/j.immuni.2004.07.01710.1016/j.immuni.2004.07.017 ↗
24. 10.1186/1556-276X-9-39310.1186/1556-276X-9-393 ↗
25. 10.3109/21691401.2014.92256810.3109/21691401.2014.922568 ↗
26. 10.3109/21691401.2014.94464610.3109/21691401.2014.944646 ↗
27. 10.3109/21691401.2014.92877810.3109/21691401.2014.928778 ↗
28. 10.1016/j.addr.2010.04.00910.1016/j.addr.2010.04.009 ↗
29. 10.3109/21691401.2014.93445610.3109/21691401.2014.934456 ↗
30. 10.7314/APJCP.2013.14.11.694910.7314/APJCP.2013.14.11.6949 ↗
31. 10.1023/A:101096330709710.1023/A:1010963307097 ↗
32. 10.1111/cbdd.1231810.1111/cbdd.12318 ↗
33. 10.2217/17435889.2.5.68110.2217/17435889.2.5.681 ↗
34. 10.1016/j.nano.2010.01.00110.1016/j.nano.2010.01.001 ↗
35. 10.1186/1556-276X-9-13110.1186/1556-276X-9-131 ↗
36. 10.1016/j.jconrel.2011.05.02510.1016/j.jconrel.2011.05.025 ↗
37. 10.1016/j.biomaterials.2013.07.02010.1016/j.biomaterials.2013.07.020 ↗
38. 10.1016/j.addr.2008.12.00910.1016/j.addr.2008.12.009 ↗
39. 10.1016/j.biomaterials.2011.01.00810.1016/j.biomaterials.2011.01.008 ↗
40. 10.1038/nature1067310.1038/nature10673 ↗
41. 10.3109/21691401.2014.95363210.3109/21691401.2014.953632 ↗
42. 10.1016/j.clinthera.2014.04.01910.1016/j.clinthera.2014.04.019 ↗
43. 10.1016/j.ijpharm.2015.08.04810.1016/j.ijpharm.2015.08.048 ↗
44. 10.1002/ange.20130288110.1002/ange.201302881 ↗
45. 10.4110/in.2013.13.5.17710.4110/in.2013.13.5.177 ↗
46. 10.1016/j.coi.2013.03.00110.1016/j.coi.2013.03.001 ↗
47. 10.1111/j.1349-7006.2002.tb01265.x10.1111/j.1349-7006.2002.tb01265.x ↗
48. Pourhassan-Moghaddam M · IET Dig Library · 2014 · 4 · 5
49. 10.1111/j.1365-2567.2005.02268.x10.1111/j.1365-2567.2005.02268.x ↗
50. 10.1007/s11095-010-0258-810.1007/s11095-010-0258-8 ↗
51. 10.1016/j.jconrel.2013.03.01010.1016/j.jconrel.2013.03.010 ↗
52. 10.3109/21691401.2014.95510810.3109/21691401.2014.955108 ↗
53. 10.1016/j.clim.2015.03.02110.1016/j.clim.2015.03.021 ↗
54. 10.1038/nri274410.1038/nri2744 ↗
55. 10.1016/j.jconrel.2008.05.00510.1016/j.jconrel.2008.05.005 ↗
56. 10.1016/j.biomaterials.2014.08.02910.1016/j.biomaterials.2014.08.029 ↗
57. 10.1016/j.biomaterials.2014.05.07710.1016/j.biomaterials.2014.05.077 ↗
58. 10.1016/j.biomaterials.2012.12.03110.1016/j.biomaterials.2012.12.031 ↗
59. 10.1016/j.biomaterials.2013.12.02410.1016/j.biomaterials.2013.12.024 ↗
60. 10.1016/j.provac.2014.07.01110.1016/j.provac.2014.07.011 ↗